Tardive and spontaneous dyskinesia incidence in the general population

BMC Psychiatry

Paul M Matiaco²  Joseph L Lyon¹  Ray M Merrill² 

[1] Department of Family and Preventive Medicine, University of Utah, Salt Lake City, UT, USA;Department of Health Science, Brigham Young University, 229-A Richards Building, Provo 84602, UT, USA

关键词: Risk factors;    Metoclopramide;    Incidence rates;    Dyskinesia;    Antipsychotic drugs;   

Others  :  1124041
DOI  :  10.1186/1471-244X-13-152

 received in 2012-12-05, accepted in 2013-05-21,  发布年份 2013

【 摘 要 】

Background

To identify the incidence rate of spontaneous dyskinesia (SD) and tardive dyskinesia (TD) in a general population and to examine the association between dykinesia and potential risk factors (exposure to metoclopramide [MCP], antipsychotic drugs, and history of diabetes and psychoses).

Methods

A retrospective cohort study was conducted for the years 2001 through 2010, based on medical claims data from the Deseret Mutual Benefit Administrators (DMBA).

Results

Thirty-four cases of TD and 229 cases of SD were identified. The incidence rate of TD among persons previously prescribed an antipsychotic or metoclopramide (MCP) (per 1,000) was 4.6 (1.6-7.7) for those with antipsychotic drug use only, 8.5 (4.8-12.2) for those with MCP use only, and 15.0 (2.0-28.1) for those with both antipsychotic and MCP use. In the general population, the incidence rate (per 100,000 person-years) of TD was 4.3 and of probable SD was 28.7. The incidence rates of TD and SD increased with age and were greater for females. Those with diabetes or psychoses had almost a 3-fold greater risk of TD than those without either of these diseases. Persons with schizophrenia had 31.2 times increased risk of TD than those without the disease. Positive associations also existed between the selected diseases and the incidence rate of probable SD, with persons with schizophrenia having 4.4 times greater risk of SD than those without the disease.

Conclusions

SD and TD are rare in this general population. Diabetes, psychoses, and especially schizophrenia are positively associated with SD and TD. A higher proportion of those with SD present with spasm of the eyelid muscles (blepharospasm) compared more with the TD cases who present more with orofacial muscular problems.

【 授权许可】

   
2013 Merrill et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Stedman JK: Stedman’s medical dictionary for the health professions and nursing. Baltimore, MD: Lippincott Williams & Wilkins; 2005.
• [2]Loonen AJ, Ivanova SA: New insights into the mechanism of drug-induced dyskinesia. CNS Spectr 2013, 18(1):15-20.
• [3]Glazer GM: Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000, 61(4):15-20.
• [4]Morganstern M, Glazer WM, Niedzwiecki D, Nouriah P: The impact of neuroleptic medication on tardive dyskinesia: a meta-analysis of published studies. AJPH 1987, 77(6):717-724.
• [5]Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J, SOHO Study Group: Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005, 66(9):1130-1133.
• [6]Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008, 21(2):151-156.
• [7]Keltner NL, Folks DG: Psychotropic Drugs. 4th edition. Maryland Heights, MO: Elsevier Mosby; 2005.
• [8]Gervin M, Browne S, Lane A, Clarke M, Waddington JL, Larkin C, O’Callaghan E: Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area. Am J Psychiatry 1998, 155(9):1202-1206.
• [9]McCreadie RG, Padmavati R, Thara R, Srinivasan TN: Spontaneous dyskinesia and parkinsonism in never-medicated, chronically ill patients with schizophrenia: 18-month follow-up. Br J Psychiatry 2002, 181:135-137.
• [10]Fenton WS, Wyatt RJ, McGlashan TH: Risk factors for spontaneous dyskinesia in schizophrenia. Arch Gen Psychiatry 1994, 51(8):643-650.
• [11]Wiholm BE, Mortimer Ö, Boethius G, Häggström JE: Tardive dyskinesia associated with Metoclopramide. BMJ 1984, 288(6416):545-547.
• [12]Ganzini L, Casey DE, Hoffman WF, McCall AL: The prevalence of metoclopramide-induced Tardive Dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993, 153:1469-1475.
• [13]Smith JM, Baldessarini RJ: Changes in prevalence, severity and recovery in tardive diskinesia with age. Arch Gen Psychiatry 1980, 37:1368-1373.
• [14]Inada T, Ohnishi K, Kamisada M, Matsuga G, Tajima O, Hashiguchi K, Shima S, Oh-e Y, Masuda Y: A prospective study of tardive diskinesia in Japan. Eur Arch Psychiatry Clin Neurosci 1991, 240(4–5):250-254.
• [15]Woerner MG, Saltz BL, Kane JM, Lieberman JA, Alvir JMJ: Diabetes and development of tardive diskinesia. Am J Psychiatry 1993, 150:966-968.
• [16]Ganzini L, Heintz RT, Hoffman WF, Casey DE: The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study. Arch Gen Psychiatry 1991, 48(3):259-263.
• [17]Raja M, Azzoni A: Diabetes is not a risk factor for tardive dyskinesia. A retrospective observational study. Hum Psychopharmacol Clin Exp 2001, 17:61-63.
• [18]Pasricha JP, Pelivanov N, Sugumar A, Jankovic J: Drug insight: from disturbed motility to disordered movement- a review of the clinical benefits and medicological risks of metoclopramide. Nature 2006, 3(3):138-148.
• [19]Tang DM, Friedenberg FK: Gastroparesis: approach, diagnostic evaluation, and management. Dis Mon 2011, 57(2):74-101.
• [20]Muench J, Hamer AM: Adverse effects of antipsychotic medications. Am Fam Physician 2010, 81(5):617-622.
• [21]Sweet RA, Mulsant BH, Rifai AH, Zubenko GS: Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients. J Geriatr Psychiatry Neurol 1992, 5(3):156-161.
• [22]Yassa R, Nastase C, Dupont D, Thibeau M: Tardive dyskinesia in elderly psychiatric patients: a 5-year study. Am J Psychiatry 1992, 149(9):1206-1211.
• [23]Merrill RM, Lyon JL, Baker RK, Gren LH: Attention deficit hyperactivity disorder and increased risk of injury. Adv Med Sci 2009, 54(1):20-26.
• [24]Merrill RM, Lindsay GB, Lyon JL: Tobacco-related cancers in the Utah compared to the United States: Quantifying the benefits of the Word of Wisdom. BYU Studies 1999, 38(4):91-105.
• [25]ICD-9-CM: International Classification of Diseases, 9th Revision; Clinical Modification. 7th edition. Los Angeles, CA: PMIC; 2006.
• [26]Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982, 39:486.
• [27]Stringer J: Basic Concepts in Pharmacology: What You Need to Know for Each Drug Class. 4th edition. New York, NY: McGraw-Hill Companies Inc.; 2011.
• [28]Alan FS, Nemeroff CB: The American Psychiatric Publishing Textbook of Psychopharmacology. 4th edition. Arlington, VA: American Psychiatric Publishing; 2009.
• [29]Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiatry 1999, 156(2):309-311.
• [30]FDA News Release: FDA requires boxed warning and risk mitigation strategy for Metoclopramide containing drugs: Agency warns against chronic use of these products to treat gastrointestinal disorders. 2009. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149533.htm webcite
• [31]Blanes C, Colom H, Moreno J, Obach R, Peraire C, Domenech J: Comparative study “in vitro” of transdermal absorption of a series of antiemetic drugs. Eur J Drug Metab Pharmacokinet 1991, 3:410-414.
• [32]Calpena AC, Blanes C, Moreno J, Obach R, Domenech J: A comparative in vitro study of transdermal absorption of antiemetics. J Pharm Sci 1994, 83(1):29-33.
• [33]Pappa S, Dazzan P: Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med 2009, 39:1065-1076.
• [34]Lee J, Poon L, Chong S: Spontaneous dyskinesia in first-episode psychosis in a Southeast Asian population. J Clin Psychopharmacol 2008, 28:536-539.
• [35]Bateman DN, Rawlins MD, Simpson JN: Extrapyramidal reactions with metoclopramide. Brit Med J 1985, 291:930-932.
• [36]Glazer WM, Morgenstern H, Doucette JT: Predicting long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993, 54:133-139.
• [37]Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L: Cigarette smoking is associated with abnormal involuntary movements in the general male population–a study of men born in 1933. Biol Psychiatry 1997, 41(6):717-723.
• [38]Chong SA, Tan EC, Tan CH: Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 2003, 28(3):185-189.
• [39]Sewell DD, Kodsi AB, Caligiuri MP, Jeste DV: Metoclopramide and tardive dyskinesia. Biol Psychiatry 1994, 36:630-632.